Introduction
Clinical trial delays are not just frustrating — they are extraordinarily costly. Industry estimates suggest that each day of delay in a pivotal trial costs a pharmaceutical company an average of $600,000 to $8 million USD in lost revenue. Multiply that by the months most trials lose to preventable setbacks, and the financial impact is staggering.
Beyond the financial cost is the human cost: patients waiting for access to potentially life-saving therapies. Every delay ripples through the entire healthcare ecosystem.
Having worked across Phase I–IV trials in oncology, infectious diseases, and medical device studies, the Conduct Research team has identified the five most common sources of clinical trial delays — and the practical strategies that prevent them.
Delay #1: Patient Recruitment and Retention Failures
Over 80% of clinical trials fail to meet their original patient enrollment timelines. This is the single most common cause of delays across all therapeutic areas.
Root causes include overly restrictive eligibility criteria, poor site selection, inadequate patient outreach, and failure to anticipate dropout rates.
Prevention Strategies
- Conduct thorough feasibility studies before finalizing inclusion/exclusion criteria
- Engage patient advocacy groups early in protocol design
- Use decentralized trial elements (remote visits, eConsent) to reduce patient burden
- Budget explicitly for retention activities, not just recruitment
Delay #2: Regulatory Submission Errors and Resubmissions
Incomplete or inaccurate regulatory submissions to Health Canada, the FDA, or other agencies can trigger requests for additional information (RAIs) that delay trial start by months. Common errors include incomplete Investigator Brochures, missing preclinical data, or inconsistencies between the protocol and the CTA.
Prevention Strategies
- Conduct pre-submission regulatory strategy meetings
- Use experienced regulatory writers who know Health Canada’s specific formatting requirements
- Build in a comprehensive internal review cycle before submission
Delay #3: Site Activation Bottlenecks
Even after regulatory approval, trials can sit dormant while site contracts, IRB/REB approvals, and investigator agreements are being finalized. The average site activation time across the industry is 4–6 months — and that is too long.
Prevention Strategies
- Begin site contract negotiations in parallel with regulatory submissions
- Work with CROs that have established site relationships and pre-negotiated master agreements
- Standardize budget templates and contract language to reduce back-and-forth
| “The sites that activate fastest are almost always the ones where the CRO already has a trusted working relationship with the principal investigator.”
— Site Activation Lead, Conduct Research |
Delay #4: Protocol Amendments
Mid-study protocol amendments are one of the most disruptive sources of delay. Every amendment requires regulatory notification, REB review, and often re-training of site staff — adding weeks or months to the timeline.
Prevention Strategies
- Invest adequate time in protocol development before submitting — rushed protocols generate amendments
- Pilot the protocol with investigator feedback before finalizing
- Conduct a thorough operational feasibility review to identify issues before they become amendments
Delay #5: Data Quality Issues and Query Resolution
Poor data quality at clinical sites generates a cascade of queries, audits, and corrective actions that slow trial progress and jeopardize data integrity. In worst-case scenarios, data issues require partial re-collection or site closure.
Prevention Strategies
- Implement robust CRF design with built-in edit checks
- Conduct proactive monitoring visits — not reactive audits
- Train site staff thoroughly at initiation and re-train proactively as needed
- Use electronic data capture (EDC) systems with real-time discrepancy flagging
Conduct Research Inc.‘s project management team is built to prevent exactly these delays. Learn more at conductresearch.ca/project-management/
How Conduct Research Addresses All Five
Conduct Research takes a proactive, prevention-first approach to trial management. From protocol design through to database lock, every milestone is managed against a detailed risk-mitigation plan that anticipates and addresses the five delay categories outlined above.
Our patient engagement team leads enrollment strategy. Our regulatory affairs experts prepare submissions with a first-pass approval mindset. And our monitoring team ensures data quality is maintained from the first patient visit to the last.
Conclusion
Clinical trial delays are not inevitable — they are largely preventable with the right planning, the right team, and the right CRO partner. Understanding where delays come from is the first step to stopping them before they start. Conduct Research brings the experience and systems needed to keep your trial on time, on budget, and on target.
